Clinical Trials Logo

BRAF NP_004324.2:p.V600X clinical trials

View clinical trials related to BRAF NP_004324.2:p.V600X.

Filter by:
  • None
  • Page 1

NCT ID: NCT01787500 Active, not recruiting - Clinical trials for Metastatic Malignant Solid Neoplasm

Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

Start date: February 15, 2013
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of vemurafenib when given together with cetuximab and irinotecan hydrochloride in treating patients with solid tumors that have spread to other parts of the body or cannot be removed by surgery. Vemurafenib and irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as cetuximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving vemurafenib with cetuximab and irinotecan hydrochloride may be a better treatment for solid tumors.